Daniel Long Sells 3,334 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total transaction of $114,922.98. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,323,321.64. This represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Septerna Trading Up 2.0%

Shares of NASDAQ:SEPN opened at $39.53 on Friday. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -48.80 and a beta of 2.29. Septerna, Inc. has a 12 month low of $10.62 and a 12 month high of $40.63. The firm’s 50-day moving average is $34.23 and its 200 day moving average is $28.93.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. As a group, equities analysts forecast that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SEPN shares. Truist Financial boosted their target price on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Septerna in a research note on Wednesday, July 1st. Raymond James Financial raised their target price on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. Finally, Stifel Nicolaus initiated coverage on shares of Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.89.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SEPN. Bank of New York Mellon Corp purchased a new stake in shares of Septerna in the 2nd quarter worth approximately $1,881,000. State of Wyoming purchased a new position in Septerna during the second quarter valued at approximately $549,000. Janus Henderson Group PLC bought a new position in Septerna in the first quarter worth approximately $21,334,000. First Light Asset Management LLC raised its stake in Septerna by 18.0% in the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after buying an additional 112,049 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Septerna during the first quarter worth $906,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.